Screener
Rapport Therapeutics, Inc. RAPP Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $63,612 | $52,645 |
| Accounts receivable | 293 | — |
| Short-term investments | 372,465 | 437,894 |
| Restricted cash | 105 | 105 |
| Prepaid expenses and other current assets | 10,381 | 7,917 |
| Total current assets | 446,856 | 498,561 |
| Property and equipment, net | 2,337 | 2,976 |
| Operating lease right of use asset, net | 8,732 | 9,909 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s restricted cash?
- Rapport Therapeutics, Inc. (RAPP) reported restricted cash of $105K in Q2 2026.
- How has Rapport Therapeutics, Inc.'s restricted cash changed year-over-year?
- Rapport Therapeutics, Inc.'s restricted cash decreased by 0.0% year-over-year, from $105K to $105K.
- What is the long-term trend for Rapport Therapeutics, Inc.'s restricted cash?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s restricted cash has grown at a 11.1% compound annual growth rate (CAGR), from $85K to $105K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Rapport Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude